Shareholders of AtaiBeckley have voted overwhelmingly in favor of Eli Lilly's acquisition, removing the most significant hurdle for the deal. The stock, however, is not trading at a level that reflects the full potential payout, as the merger consideration includes both a cash component and a contingent value right (CVR) tied to future milestones.
ATAI closed Tuesday at $7.28, down 1.5% on the day, within a narrow trading range of $7.23 to $7.40. The volume was exceptionally high, at roughly 119.7 million shares, about 9.6 times the three-month average. This activity suggests a rapid shift in the shareholder base from long-term biotech investors to merger arbitrageurs, a typical pattern as a deal approaches closing.
Under the terms of the agreement, shareholders will receive $6.75 in cash for each ATAI share, plus a non-transferable CVR that could pay up to an additional $2.50 if specified clinical and regulatory milestones are met. The $7.28 closing price therefore implies the market is assigning a value of approximately 53 cents to the CVR, which is just 21.2% of its maximum possible value.
It is important to note that this 53-cent premium is not a straightforward probability estimate. The stock price also reflects the short time remaining until the expected closing on September 11, residual deal risk, tax considerations, the time value of money, and the fact that the CVR cannot be sold or transferred except in very limited circumstances. A dollar payable years from now is worth less than a dollar today, and the CVR is an illiquid claim that offers no ownership, voting rights, or dividends.
Vote Results and Deal Timeline
According to a September 8 filing with the U.S. Securities and Exchange Commission, AtaiBeckley shareholders voted 237.8 million shares in favor of the merger, with 5.0 million against and about 555,500 abstentions. Approximately 65.6% of the company's outstanding shares were represented at the special meeting.
The company expects the transaction to close on September 11, assuming all remaining conditions are satisfied or waived. Once completed, ATAI will cease to be publicly traded, and AtaiBeckley will become a wholly-owned subsidiary of Lilly.
What the 53-Cent Premium Really Means
When subtracting the $6.75 cash payment from Tuesday's close, the residual value is exactly 53 cents. This equals 21.2% of the CVR's $2.50 maximum. If all milestones were achieved in full, total consideration would reach $9.25 per share, representing about 27% upside from Tuesday's closing price.
However, that 21.2% figure should not be interpreted as the market's precise estimate of the probability that all milestones will be met. The CVR's value is subject to significant uncertainty, including the timing of any payments, the possibility of delays or non-achievement, and the lack of liquidity. The merger proxy explicitly warns that milestones may be delayed or may never occur, and CVR holders cannot simply sell the claim if their view changes.
The Real Bet Moves to the Pipeline
Lilly's acquisition announcement valued the upfront transaction at approximately $2.8 billion, with potential CVR payments bringing the total headline value to around $3.8 billion. The key assets include BPL-003, an intranasal mebufotenin program in Phase 3 development for treatment-resistant depression, as well as VLS-01 and EMP-01 in Phase 2 development.
For Lilly shareholders, the deal adds several experimental neuropsychiatry programs without paying the full potential value upfront. The CVR structure transfers part of the clinical and regulatory risk back to AtaiBeckley holders: Lilly pays more only if the defined outcomes occur.
For ATAI holders, that same structure makes the post-closing economics less transparent. The $6.75 cash leg is straightforward once the deal closes. The additional $2.50 is a ceiling, not an entitlement. The proxy warns that milestones may be delayed or may never occur, and CVR holders cannot simply sell the claim if their view changes.
What to Watch Next
The immediate catalyst is confirmation that the merger has closed on the expected September 11 date. Until then, the stock still embeds a small amount of completion and settlement risk. After closing, attention shifts away from ATAI's daily quote and toward the precise CVR milestones, their deadlines, and Lilly's progress advancing the acquired programs.
At Tuesday's price, the cleanest interpretation is not that ATAI offers a simple 27% upside opportunity. It is that investors are paying about 53 cents today for an illiquid claim that could pay as much as $2.50 later, while expecting the $6.75 cash merger to close within days. Whether that is attractive depends far more on the probability and timing of the drug-development milestones than on the last few cents of ATAI's trading spread.
